The experimental STAT3 inhibitor WP1066 has demonstrated preclinical and clinical efficacy through inhibition of phosphorylation of STAT3, reducing target gene transcription and inducing apoptosis in cancer cells [55,56,57]. This evidence concerns the gene STAT3 and cancer.